SRPT Sarepta Therapeutics Inc.

56.65
+0.43  (1%)
Previous Close 56.22
Open 56.49
Price To book 5.25
Market Cap 3661402857
Shares 64,632,001
Volume 445,576
Short Ratio 4.65
Av. Daily Volume 2,088,225

SEC filingsSee all SEC filings

  1. 8-K - Current report 171201837
  2. S-8 - Securities to be offered to employees in employee benefit plans 171169525
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171169394
  4. 8-K - Current report 171153187
  5. CT ORDER - Confidential treatment order 171073628

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 late breaking poster presented at World Muscle Society October 7, 2017.
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy

Latest News

  1. Six promising stocks to buy for the biotech rebound ahead
  2. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  3. Sarepta Therapeutics Is on Track for Further Gains
  4. Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?
  5. Today’s Research Reports on Trending Tickers: Novavax and Sarepta Therapeutics
  6. [$$] Sarepta: Too Much Good News to Ignore
  7. Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024
  8. Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment
  9. Sarepta: Payers Gonna Pay?
  10. Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024
  11. [$$] Exonics Therapeutics Gets $40 Million for Duchenne Muscular Dystrophy Drug
  12. Sarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024
  13. Edited Transcript of SRPT earnings conference call or presentation 25-Oct-17 8:30pm GMT
  14. Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers
  15. Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051
  16. Sarepta Awaiting Approval for Exondys 51 in Europe
  17. Featured Company News - US FDA Clears Sarepta Therapeutics' IND Application for GALGT2 Gene Therapy Program; Nationwide Children's Hospital Prepared to Initiate Phase-1/2a Clinical Trials for Patients with DMD
  18. Sarepta’s Golodirsen: A Promising Treatment Option?

SEC Filings

  1. 8-K - Current report 171201837
  2. S-8 - Securities to be offered to employees in employee benefit plans 171169525
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171169394
  4. 8-K - Current report 171153187
  5. CT ORDER - Confidential treatment order 171073628
  6. 8-K - Current report 171039380
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005465
  8. 8-K - Current report 17981278
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17981043
  10. 424B5 - Prospectus [Rule 424(b)(5)] 17977541